As PD-1/PD-L1 x VEGF-targeted bispecific antibodies gain momentum in oncology, selecting the right preclinical models is becoming increasingly important. These...

Small cell lung cancer (SCLC) remains one of the most aggressive and difficult-to-treat cancers, highlighting the ongoing need for new...